ArticleEmerging infectious diseases2022
Rapid Increase of Community SARS-CoV-2 Seroprevalence during Second Wave of COVID-19, Yaoundé, Cameroon.
Article in Emerging infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Assessing SARS-CoV-2 transmission in African households from the reanalysis of serosurveys.American journal of epidemiology · 2026Article
- SARS-CoV-2 cross-sectional serosurvey across three HIV-1 therapeutic clinical trials in Africa.AIDS (London, England) · 2025Article
- Transplacental transferred anti-SARS-CoV-2 neutralizing antibodies in unvaccinated pregnant women in Cameroon occurred during the COVID-19 pandemic, but not in the pre-pandemic period.Frontiers in immunology · 2025Article
- Seroprevalence of SARS-CoV-2 in 10 Regional Capitals of Cameroon, October-December 2020.Influenza and other respiratory viruses · 2024Article
- High seroprevalence of severe acute respiratory syndrome coronavirus 2 among healthcare workers in Yaoundé, Cameroon after the first wave of Covid-19 pandemic and associated factors.Influenza and other respiratory viruses · 2024Article
- Serological surveillance reveals a high exposure to SARS-CoV-2 and altered immune response among COVID-19 unvaccinated Cameroonian individuals.PLOS global public health · 2024Article
- Seroprevalence of SARS-CoV-2 antibodies and associated risk factors during the second wave of infection in a university community in Cameroon.Influenza and other respiratory viruses · 2023Article
- Spread of SARS-CoV-2 Infection in Adult Populations in Cameroon: A Repeated Cross-Sectional Study Among Blood Donors in the Cities of Yaoundé and Douala.Journal of epidemiology and global health · 2023Article
- Large Diffusion of Severe Acute Respiratory Syndrome Coronavirus 2 After the Successive Epidemiological Waves, Including Omicron, in Guinea and Cameroon: Implications for Vaccine Strategies.Open forum infectious diseases · 2023Article
- Epidemiological situation of SARS-CoV-2 infection in Douala, the most populated and highly heterogeneous town of Cameroon: a post-vaccination update.Acta tropica · 2023Article
- Observed versus estimated actual trend of COVID-19 case numbers in Cameroon: A data-driven modelling.Infectious Disease Modelling · 2023Article
- Article
- The COVID-19 wave was already here: High seroprevalence of SARS-CoV-2 antibodies among staff and students in a Cameroon University.Journal of public health in Africa · 2023Article
- Article
- Pre-existing immunity to SARS-CoV-2 before the COVID-19 pandemic era in Cameroon: A comparative analysis according to HIV-status.Frontiers in immunology · 2023Article
- High seroprevalence of anti-SARS-CoV-2 antibodies in the capital of Chad.Journal of public health in Africa · 2022Article
- Population-based sero-epidemiological investigation of the dynamics of SARS-CoV-2 infections in the Greater Accra Region of Ghana.Scientific reports · 2022Article
- COVID-19 in Low and Middle Income Countries.Pathogens (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We conducted 2 independent population-based SARS-CoV-2 serosurveys in Yaoundé, Cameroon, during January 27-February 6 and April 24-May 19, 2021. Overall age-standardized SARS-CoV-2 IgG seroprevalence increased from 18.6% in the first survey to 51.3% in the second (p<0.001). This finding illustrates high community transmission during the second wave of COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.